Aljian Capital Management LLC Sells 275 Shares of Illumina, Inc. (NASDAQ:ILMN)

Aljian Capital Management LLC cut its holdings in Illumina, Inc. (NASDAQ:ILMN) by 13.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,705 shares of the life sciences company’s stock after selling 275 shares during the period. Aljian Capital Management LLC’s holdings in Illumina were worth $228,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Empowered Funds LLC lifted its position in shares of Illumina by 1.7% during the third quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock worth $516,000 after acquiring an additional 66 shares in the last quarter. Caprock Group LLC lifted its holdings in Illumina by 3.0% during the 3rd quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock worth $376,000 after purchasing an additional 83 shares in the last quarter. Integrated Advisors Network LLC lifted its holdings in Illumina by 2.0% during the 3rd quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock worth $585,000 after purchasing an additional 90 shares in the last quarter. Stephens Inc. AR grew its holdings in Illumina by 1.4% during the 4th quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock valued at $885,000 after buying an additional 90 shares in the last quarter. Finally, Moors & Cabot Inc. increased its position in shares of Illumina by 1.7% during the third quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company’s stock valued at $759,000 after buying an additional 95 shares during the period. 89.42% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on ILMN shares. Morgan Stanley dropped their price objective on Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a research note on Tuesday. Piper Sandler upped their price objective on shares of Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a research report on Monday. UBS Group lifted their target price on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. boosted their price target on shares of Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Finally, Citigroup cut shares of Illumina from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $190.00 to $165.00 in a research report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $159.45.

Illumina Trading Up 2.9 %

NASDAQ:ILMN opened at $103.57 on Thursday. The firm has a market capitalization of $16.43 billion, a P/E ratio of -13.49 and a beta of 1.10. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The company has a fifty day moving average of $134.32 and a 200 day moving average of $135.12. Illumina, Inc. has a 52 week low of $99.35 and a 52 week high of $156.66.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. On average, research analysts predict that Illumina, Inc. will post 4.42 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.